Liraglutide is under clinical development by Novo Nordisk and currently in the Phase I, Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Liraglutide’s likelihood of approval (LoA) and phase transition for Parkinson’s Disease took place on 07 Nov 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Liraglutide Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Liraglutide overview

Liraglutide (Victoza) is a potent anti-diabetic agent. It is the first and only human GLP-1 analog drug, synthesized by recombinant DNA expression in the species saccharomyces cerevisiae and has been engineered bio-technologically to be about 97 percent homologous to the Glucagon like peptide 1 (GLP-1) expressed in the humans through the substitution of lysine at 34th position with arginine. It is formulated as solution for subcutaneous route of administration and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular events (cardiovascular death, non- fatal  myocardial infarction, or non- fatal stroke) in adults with type 2 diabetes mellitus, established cardiovascular disease and indicated for the treatment of pediatric patients of 10 years or older with type 2 diabetes.

Liraglutide is under development for the treatment of obesity, ileal pouch-anal anastomosis, Parkinson's disease. It was also under development for non-alcoholic steatohepatitis, psoriatic arthritis and also as an adjunct therapy to insulin in Type 1 diabetes.

Novo Nordisk overview

Novo Nordisk, a subsidiary of Novo Holdings AS, is a healthcare company focused on discovering, developing, and manufacturing of innovative biological medicines. It focuses on advancing drugs for the treatment of diabetes and other serious chronic conditions, including hemophilia, human growth hormone (HGH) disorders, and obesity. The company’s portfolio includes pre-filled delivery systems for insulin; glucagon hypokit; cartridge; needles; vials; insulin; estradiol for hormone replacement; recombinant drugs for hemophilia; glucagon; and oral antidiabetic agents. the company markets its products through subsidiaries in North America, Europe, Asia, Latin America, Africa, the Middle East and Australia. Novo Nordisk is headquartered in Bagsvaerd, Denmark.

Quick View Liraglutide LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Liraglutide
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
  • Gastrointestinal
  • Metabolic Disorders
  • Musculoskeletal Disorders
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.